Myriad Genetics, a healthcare company, has acquired the exclusive North American license to specific application of novel proprietary technology used to perform pharmacokinetic analysis of therapeutic drugs in patients, from Saladax Biomedical, a developer of personalized chemotherapy management immunoassays.

BETHLEHEM, Pa., June 23 /PRNewswire/ -- A new blood test may make it easier for oncologists to accurately measure and personalize 5-fluorouracil (5-FU) dosing for patients undergoing continuous infusion chemotherapy regimens.

Saladax Biomedical has received CE mark registration in the EU for its 5-FU Personalized Chemotherapy Management assay on the Olympus AU400 clinical chemistry analyzer.

BETHLEHEM, Pa., June 17 /PRNewswire/ -- Saladax Biomedical, a company specializing in chemotherapy therapeutic drug monitoring, today announced CE mark registration in the European Union (EU) for its 5-FU Personalized Chemotherapy Management (PCM(R)) assay on the Olympus AU400 Clinical Chemistry Analyzer.